Group items tagged

Patient safety should remain a top priority in any healthcare setting. People should always receive the right advice, and pharmacists aren't 'GPs on the cheap.' Staff should be fully trained, and medical equipment should be correctly maintained at all times. In turn, this helps create a safer environment for patients and professionals alike. In this article, we'll discuss some of the factors that can enhance patient safety in healthcare settings. AUTOMATION AND MONITORING Automating processes within a facility can help streamline operations. This has the potential to reduce or eliminate human error that could result in serious injury or death. In addition, automated systems often provide instant alerts when something goes wrong - allowing medical staff to react quickly and appropriately. Automated solutions can help facilities achieve hand hygiene monitoring standards, and it's possible to schedule a demo and see their outcomes. They can reduce staff sick time and HAIs, as well as Joint Commission citations and associated costs. Monitoring helps ensure compliance with safety protocols. It's essential for improving patient safety and gaining data on all aspects of a facility's operations. It also helps organizations track the effectiveness of their protocols and procedures over time. This helps them constantly evaluate and refine their policies, to maximize patient safety benefits. ADEQUATE STAFFING In order to provide quality care, it's essential to have enough staff on hand to meet patient needs and ensure all protocols are being followed. Without this, healthcare providers may struggle to provide prompt, efficient care - which can put patient safety at risk. Adequate staffing levels should be determined by a variety of factors. They include patient numbers, the complexity of care required, and the size and layout of the facility.

Working in an office environment can be hazardous to your health. From sitting on a chair all day to exposure to harmful chemicals, many potential health hazards can occur in the workplace. While some health hazards are out of your control, there are many things you can do to help prevent them. Here are seven efficient ways to prevent health hazards at the workplace: 1. TAKE HEALTH AND SAFETY TRAINING Health and safety training is an efficient way to prevent health hazards at the workplace for several reasons. First, it helps employees to be aware of potential hazards in their work environment. This knowledge can then be used to take steps to avoid or control these hazards. Second, health and safety training provides employees with the skills and knowledge necessary to identify and report potential health hazards, especially those working in medical laboratories with frequent exposure to blood, chemicals, and other pathogens. This can help to ensure that any problems are quickly addressed and corrected. Finally, health and safety training helps to create a culture of safety in the workplace. This safety culture can encourage employees to take personal responsibility for their own health and safety, as well as the health and safety of their coworkers.

Jackie Giltrow and Jose Moss have been appointed as Chair and Vice-Chair of the Community Pharmacy Patient Safety group, respectively, bringing with them a wealth of experience and expertise in pharmacy practice. Supported by the National Pharmacy Association (NPA) and hosted by the Company Chemists' Association (CCA), the CPPSG serves as a collaborative platform for large community pharmacy organisations to openly share and learn from each other's experiences. A CPPSG Chair now, Jackie Giltrow, Clinical Governance Lead at Paydens Limited is a seasoned pharmacist and expert in risk management and patient safety. With nine years of experience as a member of the CPPSG, Giltrow's appointment represents a continuation of her longstanding dedication to advancing patient safety initiatives within community pharmacy settings.

The Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed that Ozempic has been found at two UK wholesalers on 18 October. The pre-filled falsely labelled pens have been purchased from legitimate suppliers in Austria and Germany. However, there has been no evidence that fake Ozempic has been supplied to UK patients. Dr Alison Cave, MHRA Chief Safety Officer spoke about closely with regulatory partners to ensure patients' safety. He said: "Buying semaglutide from illegally trading online suppliers significantly increases the risk of getting a product either falsified or not licensed for use in the UK. "Products purchased in this way will not meet our strict quality and safety standards, and taking such medicines may put your health at risk," he added.

Medicines and Healthcare products Regulatory Agency (MHRA) has urged the healthcare professionals to share their views on the consultation on 'how MHRA communicate with healthcare professionals to improve medicines and medical devices' safety'. Through this consultation the agency wants to review its approach to engagement with healthcare professionals to improve the safety of medicines and medical devices. "We want to ensure that healthcare professionals are receiving actionable information and guidance on safe use of medicines and medical devices that they can take into their working practice, providing timely advice to patients," said MHRA. "We need to improve the way we communicate with healthcare professionals. We want to hear from you to enable us to transform how we communicate with you and how we work together on our common goal of greater patient safety."

Professor Harry McQuillan has said community pharmacists in the UK must change their focus from an 'accuracy of supply' to a 'safety of supply' model when it comes to dealing with patients. "The main take away message from tonight's lecture is for pharmacy professionals to really challenge themselves about whether they are focused on accuracy of supply or safety of supply," he said at this year's UCL School of Pharmacy Lecture in London on Thursday, 15 June. "For our community pharmacists it must be about safety, including prescribing, and ensuring patients and citizens get the maximum benefit from prescribed medicines. "To deliver this, we need to invest in our teams - harness technology and always be willing to take the next step in a more clinical future." The Chief Executive Office of Community Pharmacy Scotland, however, noted that at a time when the UK was grappling with an unprecedented national debt crisis exacerbated by severe cost of living and spiraling inflation, community pharmacy will need to make a "compelling case" of where the priority should be in the sector. Expanding on the financial woes of the country, he compared the current national debt of the UK, which stood at a staggering 270 percent of GDP in September 2022, with the previous record-breaking national debt of 250 per cent at the end of WWII.

While responding to the consultation on hub and spoke dispensing, trade unions for pharmacists have emphasised that the patient safety and care must be the priority in hub and spoke dispensing. The Royal Pharmaceutical Society (RPS) has welcomed the opportunity provided by a change in legislation to enable community pharmacies to make use of hub and spoke dispensing but reaffirmed that patient care must be at the heart of future changes. With regards to patient safety, the Pharmaceutical Services Negotiating Committee (PSNC) considers that only Model 1 is appropriate, with manageable risks related to patient safety, and is a model that has the potential to allow the whole sector to benefit fairly. In its response to the consultation on Hub and Spoke dispensing, PSNC highlighted that Model 2 in the consultation, a hub direct to patient supply of dispensed medicines, raises patient safety issues and it cannot be supported. RPS President Professor Claire Anderson said: "In all models, patients need to continue to have access to a pharmacist at the time of supply of medicines so they have the opportunity to discuss, ask questions or raise concerns, and receive appropriate information with counselling and advice.

UK regulator has approved a new age-appropriate formulation of the Pfizer BioNTech Covid-19 vaccine for use in children aged 5 to 11 years old. The new paediatric formulation of Covid vaccine meets the required safety, quality and effectiveness standards, the Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday (December 22). Dr June Raine, MHRA chief executive said that parents and carers can be reassured that this approval has been given after robust review of safety data. These data showed a favourable safety profile for use in 5-11-year olds compared with that seen in other age groups, the regulator said. Raine said: "We have carefully considered all the available data and reached the decision that there is robust evidence to support a positive benefit risk for children in this age group.

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

Gisela Abbam today (March 14) officially succeeded Nigel Clarke as new chair of the General Pharmaceutical Council (GPhC). She was appointed in mid-Feruary. The council paid tribute to its outgoing chair for his major contribution to pharmacy regulation and his focus on patient safety for the past eight years on the role. During his tenure Clarke has overseen significant changes to how the GPhC regulates pharmacists, pharmacy technicians and pharmacies to help drive improvements in professional practice and protect patient safety. Chief executive of the GPhC, Duncan Rudkin, said: "I would like to pay tribute to Nigel for everything he has done to support continuous improvement and assure the quality and safety of pharmacy for the benefit of patients and the public.

Pharmacies are the lifeblood of community healthcare, being a vital pathway to care and support in every borough of the UK. There are 11,600 pharmacies across the country, amongst which yours stands proudly. Pharmacies obviously have a duty of care to their patients and customers, and rigorous safety practices surrounding the safe storage and dispensation of medicine - but that duty of care also extends to fellow staff. This is to say that health and safety is a paramount concern for any pharmacy or pharmacist, and that great care should always be taken to uphold the highest possible standards with regard to health and safety. With this in mind, what follows is a refresher on some of the key hazards that could give way to workplace injury in your pharmacy - and how to mitigate the risk of injury. Biological Hazards Biological hazards are ever-present, and prescient in the aftermath of the coronavirus pandemic. Though the COVID-19 virus was eventually shown not to be particularly resilient on surfaces, good practice was still to regularly disinfect surfaces and handles where possible - something which should still be a part of regular routine in your pharmacy. Likewise, face masks are a solid way to reduce the risk of infection or contamination, particularly where the handing over of biological samples is concerned.

In the pharmaceutical industry, maintaining strict hygiene standards is paramount to ensure the safety and efficacy of products. One of the critical components in achieving this goal is the utilization of sanitary clamps. These clamps play a vital role in securing various connections within pharmaceutical equipment, preventing contamination, and upholding sterile conditions. In this article, we delve into the reasons why sanitary clamps are indispensable for maintaining hygiene in pharmaceutical settings. Contamination Prevention Sanitary clamps serve as a crucial barrier against contamination in pharmaceutical environments. With stringent regulations governing pharmaceutical manufacturing, any compromise in hygiene can result in significant consequences, including product recalls and compromised patient safety. Sanitary clamps are designed to create secure and airtight connections between pipes, hoses, and other components, effectively sealing off potential entry points for contaminants such as bacteria, viruses, and particulate matter. By minimizing the risk of contamination, these clamps help pharmaceutical companies uphold the integrity of their products and adhere to regulatory standards. Moreover, the design of sanitary clamps ensures ease of cleaning and sterilization, further reducing the risk of cross-contamination between batches. Unlike traditional fastening methods that may harbor bacteria or residue, sanitary clamps feature smooth surfaces and minimal crevices, making them easier to sanitize. This not only enhances hygiene but also promotes efficiency in the cleaning process, allowing pharmaceutical manufacturers to maintain high levels of cleanliness without compromising production timelines. Overall, by preventing contamination and facilitating thorough cleaning, sanitary clamps play a crucial role in safeguarding the quality and safety of pharmaceutical products.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

NHS England has confirmed the initial sites that will test and implement Martha's Rule in the first phase of the programme. This follows the announcement in February regarding NHSE funding for the major patient safety initiative for this financial year. The scheme is named after Martha Mills, who died from sepsis at the age of 13 in 2021. She had been treated at King's College Hospital, London, where a failure to escalate her to intensive care and a lack of response to her family's concerns about her deteriorating condition contributed to her death. Martha's Rule aims to provide a consistent and understandable way for patients and families to seek an urgent review if their or their loved one's condition deteriorates and they are concerned this is not being responded to. NHS England on Monday (27 May) announced that the scheme will be implemented at 143 hospital sites across the country by March 2025.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have authorised community pharmacies throughout the UK to dispense original full packs of Valproate-containing medicines upon prescription. The necessary changes in regulations came into effect on 11 October which was strongly supported by 85 per cent of respondents concerned about risks to the unborn baby if valproate-containing medicines are used in pregnancy. The decision was made to ensure patients receive safety warnings and pictograms, including a patient card and the Patient Information Leaflet (PIL), contained in the manufacturer's original full pack. Valproate is a treatment for epilepsy and bipolar disorder but is also associated with birth defects and neurological disabilities.

The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues. NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024. As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers. It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.

"There are many different kinds of safety factors that should be adhered to when you are exercising. For instance, it is essential to warm up beforehand and warm down afterwards to prevent muscle and tendon strain and injury. It is also wise to start your exercise regime at the low end of the scale and build up gradually over some weeks, so you don't strain muscles that are weak. However, there are less obvious considerations that are often forgotten when you go off to your exercise class."

"There are many different kinds of safety factors that should be adhered to when you are exercising. For instance, it is essential to warm up beforehand and warm down afterwards to prevent muscle and tendon strain and injury. It is also wise to start your exercise regime at the low end of the scale and build up gradually over some weeks, so you don't strain muscles that are weak. However, there are less obvious considerations that are often forgotten when you go off to your exercise class."

The Association of Independent Multiple Pharmacies (AIMp) celebrated achievements of its members during the pandemic at its first annual 'ball and award' ceremony held last week in London. To highlight the important role played by pharmacy teams, the association representing community pharmacy businesses with multiple branches, introduced two award categories - for patient safety and social care. Stephen Walls from H I Weldricks won the Patient Safety Awards and Sandeep Dhami, Nadia Hussain and Sachin Basandrai from MW Phillips won the Social Care Award. Congratulating the winners, Leyla Hannbeck, CEO of AIMp, said that community pharmacy teams "have worked tirelessly to deliver patient care throughout the pandemic." David McNicol, head of sales at AAH Pharmaceuticals, noted that the country and community pharmacy witnessed the toughest 18 months, and the gathering provided an opportunity to discuss ongoing challenges.

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

The Pharmacists' Defence Association (PDA) is playing a vital role in helping pharmacists who are dealing with stress at the workplace. It launched its new awareness factsheet 'It's Time to Address Stress' last week. The factsheet looks at the causes and symptoms of stress in the workplace and provides advice on ways pharmacists can access support and improve working conditions. The association said that it recognises the well-being services offered by employers and specialist charities such as the PDA's charity partner Pharmacist Support play an important part in helping pharmacists who may be experiencing stress. However, the PDA is also committed to working with members to challenge employers to provide well workplaces and to help them to make real impact changes. This can be done by addressing the causes of stress and fulfilling their responsibilities to their employees. It added: "Under the management of Health and Safety at Work Regulations 1999, employers are required by law to protect employees from harm. Their legal obligations include identifying hazards and risks and implementing ways to reduce or eliminate them. The PDA's new factsheet highlights the importance of employers recognising the hazards causing stress as the health and safety issues they are."